DEGARELIX

Degarelix is a gonadotropin-releasing hormone (GnRH) receptor antagonist used in the treatment of advanced prostate cancer. It works by rapidly suppressing the production of testosterone, which fuels the growth of prostate cancer cells.

Indications

Advanced prostate cancer.

Dosage

Subcutaneous; given in abdomen region, starting dose is 240mg in two doses, while maintenance dose is 80mg administered every 28 days.

Contra-Indications

Known hypersensitivity to degarelix, pregnancy.

Special Precautions

Paediatric: Safety and effectiveness in paediatric group not yet established. Pregnancy: Contraindicated. Lactation: Not known if excereted in milk. Elderly: Increase sensitivity, use with caution.

Side Effects

Pain, erythema , swelling, induration  and nodule at the site , weight increase, fatigue, chills, hot flushes, increased liver enzymes, hypertension, arthralgia.

Drug Interactions

There are limited known drug interactions with Degarelix. However, patients should inform their healthcare provider about all medications, supplements, and herbal products they are taking before starting treatment.